Product
TL-925
4 clinical trials
2 indications
Indication
Allergic ConjunctivitisIndication
Dry Eye SyndromeClinical trial
A Single Center, Randomized, Double-masked, Vehicle-controlled Phase 2b Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora CAC®) ModelStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase 2b, Multicenter, Randomized, Double-masked Vehicle-controlled Study to Evaluate the Efficacy and Safety of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye DiseaseStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Single Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) ModelStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety and Tolerability of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye DiseaseStatus: Completed, Estimated PCD: 2023-07-11